Oncobiologics (ONS) & The Competition Head-To-Head Review
Oncobiologics (NASDAQ: ONS) is one of 189 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Oncobiologics to similar businesses based on the strength of its risk, valuation, profitability, dividends, analyst recommendations, earnings and institutional ownership.
Valuation & Earnings
This table compares Oncobiologics and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Oncobiologics||$2.98 million||-$53.32 million||-0.69|
|Oncobiologics Competitors||$217.40 million||-$39.57 million||-60.90|
Insider and Institutional Ownership
18.5% of Oncobiologics shares are owned by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 33.5% of Oncobiologics shares are owned by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Oncobiologics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Oncobiologics presently has a consensus price target of $9.00, indicating a potential upside of 675.86%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 14.02%. Given Oncobiologics’ higher probable upside, research analysts plainly believe Oncobiologics is more favorable than its peers.
This table compares Oncobiologics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Oncobiologics peers beat Oncobiologics on 7 of the 12 factors compared.
Oncobiologics Company Profile
Oncobiologics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform. The Company has identified approximately eight biosimilar product candidates, of which two product candidates are ONS-3010 and ONS-1045. ONS-3010 is an adalimumab (Humira) biosimilar. The Company has initiated Phase III preparatory activities for ONS-3010. Its second product candidate, ONS-1045, is a bevacizumab (Avastin) biosimilar. The Company’s other preclinical product candidate, ONS-1050, a trastuzumab (Herceptin) biosimilar, interferes with the human epidermal growth factor receptor 2 (HER2). ONS-4010 is a biosimilar to denosumab (Prolia/Xgeva), which is a human mAb. Its other biosimilar product, ONS-1055, is a biosimilar to cetuximab (Erbitux).
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.